Sorafenib and Bevacizumab to Treat Ovarian, Fallopian and Peritoneal Cancer

NCT00436215 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

55

Enrollment

NIH

Sponsor class

Conditions

Ovarian Neoplasm
Fallopian Tube Cancer
Primary Peritoneal Cancer

Interventions

DRUG: Bevacizumab
DRUG: BAY 43-9006

Sponsor

National Cancer Institute (NCI)